Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Receivables (2016 - 2025)

Regenxbio (RGNX) has 12 years of Receivables data on record, last reported at $28.8 million in Q4 2025.

  • For Q4 2025, Receivables rose 9372.04% year-over-year to $28.8 million; the TTM value through Dec 2025 reached $28.8 million, up 9372.04%, while the annual FY2025 figure was $28.8 million, 35.92% up from the prior year.
  • Receivables reached $28.8 million in Q4 2025 per RGNX's latest filing, up from $28.2 million in the prior quarter.
  • Across five years, Receivables topped out at $73.0 million in Q2 2022 and bottomed at $304000.0 in Q4 2024.
  • Average Receivables over 5 years is $35.4 million, with a median of $30.4 million recorded in 2022.
  • Peak YoY movement for Receivables: crashed 99.0% in 2024, then skyrocketed 9372.04% in 2025.
  • A 5-year view of Receivables shows it stood at $35.8 million in 2021, then skyrocketed by 58.25% to $56.6 million in 2022, then tumbled by 46.14% to $30.5 million in 2023, then plummeted by 99.0% to $304000.0 in 2024, then surged by 9372.04% to $28.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Receivables were $28.8 million in Q4 2025, $28.2 million in Q3 2025, and $21.8 million in Q2 2025.